Posaconazole: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−131%

Mortality (1)−131%

Prophylaxis (1)−131%

00.511.5+

← Posaconazole
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Posaconazole COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Prattes−131%2.31 · 1.78–3.00death60/8352/166POSACOVID

Prophylaxis−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.0001

All studies−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.000100.511.52+

Rotate screen for more detailsIncrease width for more details

← Posaconazole
reduces riskPosaconazole
increases risk →

October 2026

Posaconazole COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Prattes−131%2.31 · 1.78–3.0060/8352/166POSACOVID

Prophylaxis−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.0001

All studies−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.000100.511.52+

Rotate screen for more detailsIncrease width for more details

← Posaconazole
reduces riskPosaconazole
increases risk →

October 2026

Posaconazole COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Prattes−131%2.31 · 1.78–3.00death60/8352/166POSACOVID

Prophylaxis−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.0001

All studies−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.000100.511.52+

Rotate screen for more detailsIncrease width for more details

← Posaconazole
reduces riskPosaconazole
increases risk →

October 2026

Posaconazole COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Prattes−131%2.31 · 1.78–3.00death60/8352/166POSACOVID

Prophylaxis−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.0001

All studies−131%2.31 · 1.78–3.0060/8352/166131% higher risk

Tau² = 0.00, I² = 0.0%, p < 0.000100.511.52+

Rotate screen for more detailsIncrease width for more details

← Posaconazole
reduces riskPosaconazole
increases risk →

October 2026

Posaconazole COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Prattes−131%2.31 · 1.78–3.00death60/8352/166POSACOVID Prattes54%0.46 · 0.08–2.82misc.83 (n)83 (n)POSACOVID Prattes80%0.20 · 0.06–0.65misc.83 (n)83 (n)POSACOVID Prattes−25%1.25 · 0.26–5.88misc.83 (n)83 (n)POSACOVID

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Posaconazole
reduces riskPosaconazole
increases risk →